Thoracic surgeons and researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine found that increasing numbers of patients undergoing cancer-removal lung surgery by “anatomic lung resections”—lobectomies or segmentectomies—are able to go home safely and without complications one day after the operation, thanks to growing rates of robot-assisted surgeries and improvements in patient-centered care protocols.
Salk Institute scientists discovered a relationship between killer T-cell exhaustion and the body’s sympathetic stress response, or “fight-or-flight,” in varying cancer types in mouse and human tissue samples.
Open Philanthropy has awarded $1.38 million to Philip Low, Purdue University’s Presidential Scholar for Drug Discovery and the Ralph C. Corley Distinguished Professor of Chemistry in the College of Science, to validate a drug therapy using imatinib to treat malaria.
USC Norris Comprehensive Cancer Center has singled out mutations in 11 genes that are associated with aggressive forms of prostate cancer.
The ColoFuture study, a multi-center international clinical trial assessing the potential to integrate a portfolio of novel mRNA biomarkers into ColoAlert, has demonstrated positive topline results.
A study by University of Arizona Cancer Center researchers piloted a unique outreach strategy to foster dialogue between basic scientists and community members to demystify basic science research and facilitate culturally tailored approaches to address health disparities of vulnerable communities.
As compared to conventional, stand-alone clinical trials in advanced non-small cell lung cancer, the biomarker-driven Lung Cancer Master Protocol, or Lung-MAP, has enrolled higher percentages of patients who are older, patients who are from rural or socioeconomically deprived areas, and patients who have Medicaid or no insurance.
OneOncology finalized 25 unique oncology and hematology pathways and published each pathway inside the platform’s clinical decision support tool.
Six-year results from part 1 of the phase III CheckMate -227 trial demonstrate long-term, durable survival benefits of Opdivo (nivolumab) plus Yervoy (ipilimumab) compared to chemotherapy in the first-line treatment of patients with metastatic non-small cell lung cancer, regardless of PD-L1 expression levels.
Intensity-modulated radiation therapy should be the preferred choice when treating patients with locally advanced non-small cell lung cancer, as it reduces radiation exposure to the heart and lungs, according to researchers at MD Anderson Cancer Center.
